Cantor Fitzgerald Reaffirms Overweight on NewAmsterdam Pharma, Keeps $49 Target Ahead of Key 2026 Catalysts
Cantor Fitzgerald maintained an Overweight rating and a $49.00 price target on NewAmsterdam Pharma Co NV (NASDAQ:NAMS) after the company released fourth-quarter results. The target implies roughly 42% upside from the stock's current $34.56 level, though InvestingPro data indicates the share price may exceed its Fair Value. Multiple near- and mid-te…